{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:58:51Z","timestamp":1753441131518,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.fjurol.2024.102660","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:19:13Z","timestamp":1717136353000},"page":"102660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5962","authenticated-orcid":false,"given":"Rita","family":"Bentahila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Bensalah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Benziane-Ouaritini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Rioux-Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Correas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Belhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.fjurol.2024.102660_bib0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102660_bib0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.euo.2020.02.001","article-title":"Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel","volume":"3","author":"Abu-Ghanem","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"12 Suppl.","key":"10.1016\/j.fjurol.2024.102660_bib0150","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102660_bib0155","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102660_bib0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","volume":"84","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102660_bib0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clon.2022.06.007","article-title":"Stereotactic body radiotherapy for renal cell carcinoma: oncological and renal function outcomes","volume":"35","author":"Glicksman","year":"2023","journal-title":"Clin Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102660_bib0170","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102660_bib0175","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon.16.2","article-title":"Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma","volume":"12","author":"Siva","year":"2016","journal-title":"Future Oncol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102660_bib0180","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.purol.2022.07.146","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2022-2024: management of kidney cancer","volume":"32","author":"Bigot","year":"2022","journal-title":"Prog Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102660_bib0185","doi-asserted-by":"crossref","first-page":"100304","DOI":"10.1016\/j.esmoop.2021.100304","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma","volume":"6","author":"Kanesvaran","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102660_bib0190","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for\u00a0\u2265\u00a0T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102660_bib0195","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102660_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.04.010","article-title":"Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus","volume":"33","author":"Haddad","year":"2015","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102660_bib0205","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/JU.0000000000000111","article-title":"Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK","volume":"201","author":"Correa","year":"2019","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102660_bib0210","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cancers13133129","article-title":"Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience","volume":"13","author":"Grelier","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102660_bib0215","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clon.2021.03.002","article-title":"Patient-reported quality of life following stereotactic body radiation therapy for primary kidney cancer\u00a0\u2013\u00a0Results from a prospective cohort study","volume":"33","author":"Swaminath","year":"2021","journal-title":"Clin Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102660_bib0220","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3390\/jcm11071829","article-title":"PSMA PET\/CT in renal cell carcinoma: an overview of current literature","volume":"11","author":"Muselaers","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102660_bib0225","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1120\/jacmp.v17i6.6406","article-title":"Evaluation of kidney motion and target localization in abdominal SBRT patients","volume":"17","author":"Sonier","year":"2016","journal-title":"J Appl Clin Med Phys"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102660_bib0230","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-018-4916-2","article-title":"TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney\u00a0\u2013\u00a0FASTRACK II","volume":"18","author":"Siva","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102660_bib0235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","article-title":"Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial","volume":"110","author":"Margulis","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102660_bib0240","first-page":"100592","article-title":"Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer","volume":"39","author":"Tran","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102660_bib0245","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102660_bib0250","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.prro.2022.06.012","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell cancer: 24-month results of the RSR1 phase 1 dose escalation study","volume":"13","author":"Lapierre","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102660_bib0255","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00384-013-1717-6","article-title":"Severe intestinal toxicity after stereotactic ablative radiotherapy for abdominopelvic malignancies","volume":"28","author":"Bae","year":"2013","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102660_bib0260","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102660_bib0265","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102660_bib0270","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T22:02:22Z","timestamp":1721167342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024001177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2950393024001177"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102660","relation":{},"ISSN":["2950-3930"],"issn-type":[{"type":"print","value":"2950-3930"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102660"}}